Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hypoglycemia in diabetes.

Philip E Cryer1, Stephen N Davis, Harry Shamoon

  • 1Division of Endocrinology, Diabetes and Metabolism, Washington University School of Medicine, St. Louis, Missouri 63110, USA. pcryer@im.wustl.edu

Diabetes Care
|May 27, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hot flashes, cold feet: a cautious embrace of regulatory reform.

The journals of gerontology. Series A, Biological sciences and medical sciences·2026
Same author

What is our current understanding of insulin-derived amyloidosis?

Expert opinion on drug safety·2025
Same author

A safety review of approved oral agents for treating type 2 diabetes and associated diseases in pregnant patients.

Expert opinion on drug safety·2025
Same author

Treatment of diabetes in patients with advanced chronic kidney disease or kidney failure.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2025
Same author

Drugs stimulating insulin secretion in early clinical development for the treatment of type 1 diabetes: what's new?

Expert opinion on investigational drugs·2024
Same author

Evaluating semaglutide + LAI-287 (IcoSema) for the treatment of diabetes mellitus type II.

Expert opinion on pharmacotherapy·2024
Same journal

Type 1 Diabetes Driven by Residual Recipient T Cells After Hematopoietic Cell Transplantation: A Case Report.

Diabetes care·2026
Same journal

Predicting the Path to Attrition: Multidomain Risk Assessment in Diabetic Foot Ulcer Offloading Randomized Controlled Trials.

Diabetes care·2026
Same journal

Habituation to Elevated Glucose Levels in Type 1 Diabetes: Function and Well-Being in Guideline-Based Versus Typical Glycemic Range.

Diabetes care·2026
Same journal

The Correlation Between Fear and Perceived Frequency of Hypoglycemia and Continuous Glucose Monitoring Metrics in Adults With Type 1 Diabetes Using Diabetes Technology: A One-Year Analysis.

Diabetes care·2026
Same journal

A Secular Increase in the Incidence of Islet Autoimmunity Among Colorado Children With Moderate-Risk HLA Genotypes.

Diabetes care·2026
Same journal

Clinical and Biochemical Recovery From Immune Checkpoint Inhibitor-Induced Diabetes With Seroconversion of GAD Antibodies.

Diabetes care·2026
See all related articles

Iatrogenic hypoglycemia in diabetes is often unrecognized and dangerous, leading to recurrent episodes. Avoiding hypoglycemia for 2-3 weeks can reverse unawareness and improve glucose counterregulation, enhancing patient safety.

Area of Science:

  • Endocrinology
  • Metabolic Disorders
  • Diabetes Mellitus Research

Background:

  • Iatrogenic hypoglycemia is a significant cause of morbidity and mortality in type 1 and type 2 diabetes.
  • Hypoglycemia, particularly unawareness, impairs glucose counterregulation, creating a cycle of recurrent episodes.
  • Current insulin replacement therapies often fail to achieve physiological glucose regulation safely.

Purpose of the Study:

  • To elucidate the mechanisms of iatrogenic hypoglycemia in diabetes.
  • To outline strategies for minimizing hypoglycemia while optimizing glycemic control.
  • To emphasize the importance of addressing hypoglycemia unawareness and compromised glucose counterregulation.

Main Methods:

  • Review of existing literature on hypoglycemia pathophysiology and clinical management in diabetes.

Related Experiment Videos

  • Analysis of the interplay between insulin excess, glucose counterregulation, and hypoglycemia unawareness.
  • Discussion of risk factors contributing to iatrogenic hypoglycemia.

    • Main Results:

    • Iatrogenic hypoglycemia results from insulin excess and impaired glucose counterregulation, often exacerbated by antecedent hypoglycemia.
    • Hypoglycemia unawareness is linked to defective sympathoadrenal responses and can be reversed by short-term avoidance of low glucose levels.
    • Clinical management involves addressing hypoglycemia risk factors and adopting individualized glycemic therapy.

    Conclusions:

    • Short-term avoidance of hypoglycemia is crucial for reversing unawareness and improving counterregulatory responses.
    • Physiological insulin replacement and better management of glucose counterregulation are needed for safe euglycemia.
    • A comprehensive approach addressing insulin dosing, patient behavior, and compromised counterregulation is essential for minimizing hypoglycemia in diabetes.